Amarantus BioScience Holdings (OTC: AMBS) is a biotech company focused on developing therapeutic products with potential for orphan drug designation in neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company’s lead therapeutic program is indicated for the treatment of problems associated with Parkinson’s. It also haves exclusive worldwide license rights of Engineered Skin Substitute for severe burns. Amarantus’ lead neurological diagnostic product is indicated to diagnose Alzheimer’s disease. The company is actively exploring strategic options for Amarantus Diagnostics, including a potential spin-off, to derive the full value of its neuro-diagnostics business. For more information, visit the company’s website at www.amarantus.com